← RenovoRx, Inc. (RNXT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
RenovoRx, Inc. (RNXT)
Surgical & Medical Instruments & Apparatus · market cap $77M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
10
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
RenovoRx, Inc. (RNXT) is a small-cap pharmaceutical company with a $39M market cap and approximately $12.4M in cash, implying roughly 10 months of runway. Its lead asset is Zesteem (estradiol) in a Phase 3 trial for burns, with a broader pipeline spanning scar reduction (avotermin/Juvista, Juvidex, Prevascar) and a gemcitabine program in locally advanced pancreatic cancer. The company carries minimal revenue ($1M in 2025) against sustained annual net losses of ~$10–11M.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2027-01-01 (est.)Phase 3imp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Avotermin (RN1001) | Phase 2 | Cicatrix |
| estradiol (Zesteem) | Phase 3 | Burn |
| Juvidex | Phase 2 | Cicatrix |
| Avotermin | Phase 2 | Cicatrix |
| Juvista (avotermin) | Phase 3 | Cicatrix |
| Avotermin (Juvista) | Phase 2 | Cicatrix |
| Intradermal avotermin | Phase 2 | Cicatrix |
| Mannose-6-Phosphate (Juvidex) | Phase 2 | Wound |
| Zesteem | Phase 2 | Cicatrix |
| Prevascar | Phase 2 | Cicatrix |
Price & technical context
3-month
+68.5%
6-month
+59.8%
12-month
+22.0%
52-wk range
$0.73–$2.52
vs 50-day MA
+5.4%
vs 200-day MA
+45.5%
Realized vol
87.0%
Max drawdown
-52.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RNXT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.